Retour

SANOFI-AVENTIS (EPA:SAN) Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate

Directive transparence : information réglementée

28/09/2021 08:00

15/05/2022 09:30

Press Release: Sarclisa® (isatuximab) combination provides unprecedented...

11/05/2022 08:00

Press Release: New nirsevimab data analyses reinforce efficacy against RSV

04/05/2022 12:00

Press Release: Foundation S: Sanofi’s new philanthropic spearhead

26/04/2022 20:28

Sanofi: Information concerning the total number of voting rights and...

26/04/2022 12:47

Press Release: Sanofi teams up with McLaren Racing to accelerate...

04/04/2022 12:00

Press Release: Sanofi launches first-in-pharma Diversity, Equity &...

29/03/2022 03:00

Press Release: Sanofi continues on path to industry leadership in...

28/03/2022 09:00

Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and...

26/03/2022 17:45

Sanofi: Information concerning the total number of voting rights and...

26/03/2022 15:00

Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent®...

Voir tous les communiqués de SANOFI-AVENTIS